Clinical Trial Update: Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ado-trastuzumab emtansine versus standard chemotherapy with docetaxel plus trastuzumab or trastuzumab deruxtecan in HER2-expressing sal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Carcinoma
• Unresectable Salivary Gland Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)
• Trastuzumab Deruxtecan (Enhertu) (trastuzumab deruxtecan)
• ado-trastuzumab emtansine (Kadcyla) (ado-trastuzumab emtansine)

Snippet

Sponsor: NRG Oncology | Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Status: RECRUITING